List view / Grid view
Tasca Therapeutics is using chemical proteomics to map lipid-binding pockets on proteins. By targeting auto-palmitoylation, the company aims to turn previously undruggable cancer drivers into viable therapeutic targets.
Vanitha Margan, Global Product Manager for Bio-Plex Multiplex Immunoassays at Bio-Rad Laboratories, reveals how multiplexing is being used to realise the full potential of extracellular vesicles in disease monitoring.
BCG’s Chris Meier outlines how advances in AI and new UK policies could accelerate drug development, streamline clinical trials and strengthen the country’s life sciences sector.
Frontier Bio’s vascular bioengineering research connects tissue modelling with graft development to advance regenerative medicine and drug discovery.
Demands on central laboratories are consistently increasing, heightening the challenge to deliver operational excellence and the highest standard of scientific integrity with both speed and agility. ICON Laboratories is transforming the way we leverage data and intelligent operational models to meet evolving trial needs.
Drug-resistant infections are on the rise, endangering global health. Neil Murray from ReNewVax explains how the company’s universal pneumococcal vaccine, RVX-001, could reduce antibiotic use and help curb antimicrobial resistance.
Everyone talks about AI speeding up drug discovery, but Eric Ma explains why, without clean data and statistical discipline, it can actually do the opposite.
What if treating blindness did not mean fixing a single faulty gene? Find out how modifier gene therapy is designed to protect vision by targeting broader retinal pathways.
Bigger isn’t always better. In drug discovery, Dr Michael Ritchie argues that the future belongs not to those with the most data, but to those who understand its biological depth.
AI is transforming biomarker analysis in early drug discovery, revealing hidden biological patterns that improve target discovery, patient selection and trial design for more precise and predictive R&D.
Pioneering circular RNA could redefine what the future of gene therapy looks like. Erik Digman Wiklund, CEO of Circio, shares how his company’s platform is enhancing gene expression and tackling toxicity challenges through smarter design and scientific collaboration.
From richer biomarker content to patient-friendly sampling, first-void urine is emerging as a promising tool in precision health. Here is why scientists are paying attention.
Advances in formulation science and device technology are transforming nasal drug delivery, enhancing absorption, stability and patient adherence. This article examines the innovations driving its growth and highlights future applications ranging from systemic treatments to nose-to-brain therapies and vaccines.
Current obesity drug development remains overly focused on short-term weight reduction, despite obesity being a chronic, multifactorial disease. Broader, mechanism-driven approaches are needed to ensure durable efficacy, safety and accessibility.
With its lead candidate DM199, DiaMedica Therapeutics is advancing a recombinant form of KLK1 to restore blood flow, improve endothelial function and address unmet needs in the treatment of stroke and preeclampsia.
